Vandana Singh
·
September 5, 2025
Benzinga
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
read more
June 20, 2025
Fortune
September 2, 2025
August 26, 2025
Barchart